The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm
efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will
remain on-study until study completion, which will occur when all primary endpoint events
(all-cause mortality or cardiac hospitalizations) have been reached.